Session Details

SFC Session 2: Raising capital for CGT industrialization
Thursday, May 28, 2020 03:45 PM - 05:00 PM 
In this session we will discuss the current landscape of cell and gene therapies from the investor’s perspective. As these therapies reach more advanced stages of development and eventually commercialization the capital requirements will continue to increase – and along with this the need to expand the scope of the investor base.  We aim to address the following questions:

-How do investors characterize opportunities for CGT companies relative to more traditional drug modalities?
-What role does pharma need to play to support the CGT ecosystem?
-Will investor appetite for CGT continue to increase, or have we hit a local maximum?

No Speakers Found.